Stock Stories - Bamboo Works - China stock insights for global investors

Stories About 1801.HK

Innovent’s $10.5 billion deal with Pfizer

Innovent’s $10.5 billion deal marks new model for China drugmakers

2026-06-04

Innovent’s license deal

So big but so what? Innovent’s license deal fails to excite investors

2025-10-30

The biopharmaceutical company had planned to sell a 20% stake in its international unit to the group’s founder, but the cheap price sparked a crisis of market confidence.

Innovent ditches low-value stake sale after investor outcry

2024-11-07

This biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug.

Innovent Bio hopes for plus-sized profits from obesity drug

2024-09-05

Founded in 2011 and listed on the Hong Kong Stock Exchange in 2018, Innovent develops and sells innovative drugs to treat tumors and other diseases.

FAST NEWS: Innovent Bio’s loss narrows on strong sales growth

2024-03-21

Biotech company Innovent Biologics announced on Thursday it recorded product revenue of more than 1.6 billion yuan in the third quarter, up 45% year-on-year.

FAST NEWS: Innovent Bio’s revenue soars on strong cancer treatment sales

2023-11-03

Biotech company Innovent Biologics announced on Tuesday it will place 68 million new shares, representing approximately 4.22% of the enlarged issued share capital.

FAST NEWS: Innovent Bio to raise HK$2.4 billion in share placement

2023-09-12

Discover hidden China stock gems in our weekly newsletter

Follow us

Subscribe to Our Free eNewsletter

Check out our content with some of our syndication partners